Michael C Donohue

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/491086/michael-c-donohue-publications-by-year.pdf
Version: 2024-04-16

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79 papers	6,817 citations	34 h-index	82 g-index
94 ext. papers	8,285 ext. citations	5.9 avg, IF	5.55 L-index

#	Paper	IF	Citations
79	Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.. *journal of prevention of Alzheimer's disease, The*, **2022**, 9, 255-261	3.8	
78	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume.. *GeroScience*, **2022**, 1	8.9	1
77	The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial. *journal of prevention of Alzheimer's disease, The*, **2021**, 8, 59-67	3.8	14
76	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. *JAMA Neurology*, **2021**, 78, 396-406	17.2	41
75	Serratus anterior plane versus paravertebral nerve blocks for postoperative analgesia after non-mastectomy breast surgery: a randomized controlled non-inferiority trial. *Regional Anesthesia and Pain Medicine*, **2021**, 46, 773-778	3.4	3
74	Time between milestone events in the Alzheimer's disease amyloid cascade. *NeuroImage*, **2021**, 227, 117676	7.9	5
73	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. *JAMA Neurology*, **2021**, 78, 293-301	17.2	21
72	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2021**, 7, e12135	6	4
71	Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention. *Brain Communications*, **2020**, 2, fcaa007	4.5	32
70	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. *JAMA Neurology*, **2020**, 77, 735-745	17.2	81
69	Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. *Alzheimer's and Dementia*, **2020**, 16, 797-803	1.2	1
68	Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials. *journal of prevention of Alzheimer's disease, The*, **2020**, 7, 213-218	3.8	9
67	Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring* , **2020**, 12, e12118	5.2	3
66	The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview. *journal of prevention of Alzheimer's disease, The*, **2020**, 7, 208-212	3.8	11
65	The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults. *Annals of Clinical and Translational Neurology*, **2020**, 7, 776-785	5.3	15
64	Predicting diagnosis and cognition with F-AV-1451 tau PET and structural MRI in Alzheimer's disease. *Alzheimer's and Dementia*, **2019**, 15, 570-580	1.2	43
63	Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). *Journal of Alzheimer's Disease*, **2019**, 70, 131-138	4.3	16

62	Continuous Popliteal-Sciatic Blocks for Postoperative Analgesia: Traditional Proximal Catheter Insertion Superficial to the Paraneural Sheath Versus a New Distal Insertion Site Deep to the Paraneural Sheath. *Anesthesia and Analgesia*, **2019**, 128, e104-e108	3.9	3
61	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. *Alzheimer's and Dementia*, **2019**, 15, 615-624	1.2	4
60	Predicting the course of Alzheimer's progression. *Brain Informatics*, **2019**, 6, 6	5.9	18
59	The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 308-318	6	6
58	Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. *NeuroImage*, **2019**, 186, 446-454	7.9	8
57	Bayesian latent time joint mixed effect models for multicohort longitudinal data. *Statistical Methods in Medical Research*, **2019**, 28, 835-845	2.3	23
56	Disease progression models for dominantly-inherited Alzheimer's disease. *Brain*, **2018**, 141, 1244-1246	11.2	1
55	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. *Alzheimer's and Dementia*, **2018**, 14, 1077-1087	1.2	52
54	Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. *Neurodegenerative Diseases*, **2018**, 18, 173-190	2.3	8
53	Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 657-668	5.2	9
52	Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. *Alzheimer's and Dementia*, **2018**, 14, 1397-1405	1.2	5
51	Sex, amyloid, and APOE 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. *Alzheimer's and Dementia*, **2018**, 14, 1193-1203	1.2	111
50	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid *Alzheimer's and Dementia*, **2017**, 13, 1004-1012	1.2	96
49	Continuous Transversus Abdominis Plane Nerve Blocks: Does Varying Local Anesthetic Delivery Method-Automatic Repeated Bolus Versus Continuous Basal Infusion-Influence the Extent of Sensation to Cold?: A Randomized, Triple-Masked, Crossover Study in Volunteers. *Anesthesia and Analgesia*, **2017**, 124, 1298-1303	3.9	14
48	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. *JAMA - Journal of the American Medical Association*, **2017**, 317, 2305-2316	27.4	214
47	Cross-validation of optimized composites for preclinical Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 123-129	6	9
46	Infection Rates of Electrical Leads Used for Percutaneous Neurostimulation of the Peripheral Nervous System. *Pain Practice*, **2017**, 17, 753-762	3	41
45	Using social and mobile tools for weight loss in overweight and obese young adults (Project SMART): a 2 year, parallel-group, randomised, controlled trial. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 747-755	18.1	87

44	Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. *Neurology*, **2016**, 86, 1887-96	6.5	37
43	Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment. *Neurobiology of Aging*, **2016**, 48, 172-181	5.6	22
42	Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. *JAMA Neurology*, **2015**, 72, 446-54	17.2	103
41	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. *Alzheimer's and Dementia*, **2015**, 11, 865-84	1.2	132
40	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. *Alzheimer's and Dementia*, **2015**, 11, 734-9	1.2	49
39	The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. *Alzheimer's and Dementia*, **2015**, 11, 823-31	1.2	41
38	Clinical trial management of participant recruitment, enrollment, engagement, and retention in the SMART study using a Marketing and Information Technology (MARKIT) model. *Contemporary Clinical Trials*, **2015**, 42, 185-95	2.3	45
37	Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. *JAMA Neurology*, **2015**, 72, 554-60	17.2	39
36	Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. *Alzheimer's and Dementia*, **2015**, 11, 1069-79	1.2	16
35	The transitional association between β-amyloid pathology and regional brain atrophy. *Alzheimer's and Dementia*, **2015**, 11, 1171-9	1.2	29
34	Students at Risk for Being Reported for Cheating. *Journal of Academic Ethics*, **2015**, 13, 217-228	1.5	29
33	A randomized, triple-masked, active-controlled investigation of the relative effects of dose, concentration, and infusion rate for continuous popliteal-sciatic nerve blocks in volunteers. *British Journal of Anaesthesia*, **2015**, 114, 121-9	5.4	15
32	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2015**, 2, 534-47	5.3	25
31	Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2015**, 45, 1175-84	4.3	23
30	The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. *Frontiers in Behavioral Neuroscience*, **2015**, 9, 239	3.5	60
29	Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. *Brain*, **2015**, 138, 772-83	11.2	169
28	Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. *Brain*, **2014**, 137, 1550-61	11.2	109
27	Design and implementation of a randomized controlled social and mobile weight loss trial for young adults (project SMART). *Contemporary Clinical Trials*, **2014**, 37, 10-8	2.3	72

26	Estimating long-term multivariate progression from short-term data. *Alzheimer's and Dementia*, **2014**, 10, S400-10	1.2	101
25	The A4 study: stopping AD before symptoms begin?. *Science Translational Medicine*, **2014**, 6, 228fs13	17.5	455
24	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2014**, 1, 534-43	5.3	78
23	The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. *JAMA Neurology* , **2014**, 71, 961-70	17.2	372
22	Emerging amyloid pathology and accelerated cortical atrophy. *JAMA Neurology*, **2014**, 71, 725-34	17.2	43
21	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurology, The*, **2013**, 12, 207-16	24.1	2557
20	O3□3□1: Update on hypothetical model of Alzheimer's disease biomarkers **2013**, 9, P521-P522		0
19	Developing dementia prevention trials: baseline report of the Home-Based Assessment study. *Alzheimer Disease and Associated Disorders*, **2013**, 27, 356-62	2.5	13
18	F3-04-01: The A4 trial: Anti-amyloid treatment of asymptomatic Alzheimer's disease **2012**, 8, P425-P426		14
17	Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials. *Journal of Nutrition, Health and Aging*, **2012**, 16, 360-4	5.2	13
16	Continuous femoral nerve blocks: the impact of catheter tip location relative to the femoral nerve (anterior versus posterior) on quadriceps weakness and cutaneous sensory block. *Anesthesia and Analgesia*, **2012**, 115, 721-7	3.9	23
15	Continuous femoral nerve blocks: decreasing local anesthetic concentration to minimize quadriceps femoris weakness. *Anesthesiology*, **2012**, 116, 665-72	4.3	60
14	The relative efficiency of time-to-threshold and rate of change in longitudinal data. *Contemporary Clinical Trials*, **2011**, 32, 685-93	2.3	24
13	Statistics and Clinical Data Analysis: A Reference Guide **2011**, 651-672		
12	Requiring an amyloid-□1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. *Alzheimer's and Dementia*, **2011**, 7, 245-6; author reply 247-9	1.2	4
11	Continuous femoral nerve blocks: varying local anesthetic delivery method (bolus versus basal) to minimize quadriceps motor block while maintaining sensory block. *Anesthesiology*, **2011**, 115, 774-81	4.3	103
10	Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years old. *Alzheimer Disease and Associated Disorders*, **2010**, 24, 256-63	2.5	15
9	The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. *Alzheimer's and Dementia*, **2010**, 6, 257-64	1.2	85

8	Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. *Alzheimer's and Dementia*, **2010**, 6, 239-46	1.2	308
7	The association between lower extremity continuous peripheral nerve blocks and patient falls after knee and hip arthroplasty. *Anesthesia and Analgesia*, **2010**, 111, 1552-4	3.9	271
6	Continuous peripheral nerve blocks: is local anesthetic dose the only factor, or do concentration and volume influence infusion effects as well?. *Anesthesiology*, **2010**, 112, 347-54	4.3	76
5	Applications of Neuroimaging to Disease-Modification Trials in Alzheimer Disease. *Behavioural Neurology*, **2009**, 21, 129-136	3	16
4	Pediatricians' weight assessment and obesity management practices. *BMC Pediatrics*, **2009**, 9, 19	2.6	35
3	Asynergistic Regression Based on Maximized Rank Correlation. *Communications in Statistics Part B: Simulation and Computation*, **2007**, 37, 92-105	0.6	
2	Parental ability to discriminate the weight status of children: results of a survey. *Pediatrics*, **2007**, 120, e112-9	7.4	89
1	Time between milestone events in the Alzheimer disease amyloid cascade		1